Syndax Pharmaceuticals
Clinical trials sponsored by Syndax Pharmaceuticals, explained in plain language.
-
New drug axatilimab aims to slow lung scarring in IPF patients
Disease control OngoingThis study tests a drug called axatilimab in 145 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The goal is to see if axatilimab can slow the decline in lung function over 26 weeks compared to a placebo. Participants…
Phase: PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Last-resort leukemia drug made available to more patients
Disease control NO_LONGER_AVAILABLEThis program provides an experimental drug, SNDX-5613, to people with relapsed or treatment-resistant acute leukemias who have a specific genetic change and no other approved options. Participants must be at least 6 months old and cannot join other studies of this drug. The goal …
Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New hope for stubborn transplant complication?
Disease control OngoingThis study tests a drug called axatilimab in 241 people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where donor cells attack the body. Participants had already tried at least two other treatments without success. The goal is to see …
Phase: PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:40 UTC